PortfoliosLab logoPortfoliosLab logo
BIB vs. ARKG
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BIB vs. ARKG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BIB achieves a 12.50% return, which is significantly lower than ARKG's 24.30% return. Over the past 10 years, BIB has outperformed ARKG with an annualized return of 9.71%, while ARKG has yielded a comparatively lower 8.67% annualized return.


BIB

1D
1.97%
1M
9.49%
YTD
12.50%
6M
8.62%
1Y
100.86%
3Y*
19.65%
5Y*
-0.74%
10Y*
9.71%

ARKG

1D
-1.07%
1M
17.41%
YTD
24.30%
6M
19.48%
1Y
52.71%
3Y*
3.17%
5Y*
-16.56%
10Y*
8.67%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BIB vs. ARKG - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
BIB
ProShares Ultra Nasdaq Biotechnology
12.50%59.21%-9.84%-1.06%-28.85%-6.02%39.79%46.71%-24.93%40.49%
ARKG
ARK Genomic Revolution Multi-Sector ETF
24.30%23.04%-28.24%16.22%-53.90%-33.92%180.40%44.00%-1.26%46.61%

Correlation

The correlation between BIB and ARKG is 0.67, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.67

Correlation (3Y)
Calculated over the trailing 3-year period

0.73

Correlation (5Y)
Calculated over the trailing 5-year period

0.78

Correlation (10Y)
Calculated over the trailing 10-year period

0.79

Correlation (All Time)
Calculated using the full available price history since Oct 31, 2014

0.77

The correlation between BIB and ARKG shifts across timeframes, from 0.67 (1 year) to 0.79 (10 years), reflecting how their relationship changes across market environments.

BIB vs. ARKG - Sectors Allocation Comparison


Sectors
BIB
ARKG

Healthcare

62.9%
99.3%

Financial Services

6.8%
0.5%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

BIB
62.9%
ARKG
99.3%

Financial Services

BIB
6.8%
ARKG
0.5%

Basic Materials

BIB

-

ARKG

-

Communication Services

BIB

-

ARKG

-

Consumer Cyclical

BIB

-

ARKG

-

Consumer Defensive

BIB

-

ARKG

-

Energy

BIB

-

ARKG

-

Industrials

BIB

-

ARKG

-

Real Estate

BIB

-

ARKG

-

Technology

BIB

-

ARKG

-

Utilities

BIB

-

ARKG

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BIB vs. ARKG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIB
BIB Risk / Return Rank: 8080
Overall Rank
BIB Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
BIB Sortino Ratio Rank: 7373
Sortino Ratio Rank
BIB Omega Ratio Rank: 6565
Omega Ratio Rank
BIB Calmar Ratio Rank: 9292
Calmar Ratio Rank
BIB Martin Ratio Rank: 8888
Martin Ratio Rank

ARKG
ARKG Risk / Return Rank: 3636
Overall Rank
ARKG Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
ARKG Sortino Ratio Rank: 3838
Sortino Ratio Rank
ARKG Omega Ratio Rank: 3434
Omega Ratio Rank
ARKG Calmar Ratio Rank: 4040
Calmar Ratio Rank
ARKG Martin Ratio Rank: 3232
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIB vs. ARKG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BIBARKGDifference
Sharpe ratioReturn per unit of total volatility

+1.26

Sortino ratioReturn per unit of downside risk

+1.16

Omega ratioGain probability vs. loss probability

1.36

1.22

+0.14

Calmar ratioReturn relative to maximum drawdown

5.99

1.93

+4.07

Martin ratioReturn relative to average drawdown

18.30

4.58

+13.72

BIB vs. ARKG - Sharpe Ratio Comparison

The current BIB Sharpe Ratio is 2.51, which is higher than the ARKG Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of BIB and ARKG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BIB vs. ARKG - Drawdown Comparison

The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for BIB and ARKG.


Loading charts...

Drawdown Indicators


BIBARKGDifference

Max Drawdown

Largest peak-to-trough decline

-67.24%

-83.59%

+16.35%

Max Drawdown (1Y)

Largest decline over 1 year

-16.92%

-27.51%

+10.59%

Max Drawdown (3Y)

Largest decline over 3 years

-45.30%

-51.96%

+6.66%

Max Drawdown (5Y)

Largest decline over 5 years

-65.86%

-80.18%

+14.32%

Max Drawdown (10Y)

Largest decline over 10 years

-66.20%

-83.59%

+17.39%

Current Drawdown

Current decline from peak

-17.29%

-67.78%

+50.49%

Average Drawdown

Average peak-to-trough decline

-32.71%

-36.02%

+3.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.53%

11.53%

-6.00%

Volatility

BIB vs. ARKG - Volatility Comparison

The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 13.56%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 15.19%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BIBARKGDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.56%

15.19%

-1.63%

Volatility (6M)

Calculated over the trailing 6-month period

31.65%

30.91%

+0.74%

Volatility (1Y)

Calculated over the trailing 1-year period

40.43%

42.54%

-2.11%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

43.60%

45.93%

-2.33%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

46.39%

41.29%

+5.10%

BIB vs. ARKG - Expense Ratio Comparison

BIB has a 0.95% expense ratio, which is higher than ARKG's 0.75% expense ratio.


Dividends

BIB vs. ARKG - Dividend Comparison

BIB's dividend yield for the trailing twelve months is around 0.55%, while ARKG has not paid dividends to shareholders.


PositionTTM202520242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF
0.00%0.00%0.00%0.00%0.00%0.62%0.85%3.14%0.82%1.34%
BIB
ProShares Ultra Nasdaq Biotechnology
0.55%0.77%1.69%0.07%0.03%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


BIB and ARKG have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ARKG has higher volatility (15.19%) compared to BIB (13.56%). In terms of maximum drawdown, BIB dropped -67.24% vs ARKG's -83.59%.

On 10-year performance, BIB leads with 9.71% vs 8.67% for ARKG. On fees, ARKG is cheaper at 0.75% per year. On volatility, BIB has been the lower-risk option at 13.56%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, BIB has performed better with a 9.71% return vs 8.67%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

ARKG is cheaper with a 0.75% expense ratio, compared with 0.95% for BIB.

BIB has the higher dividend yield at 0.55%, compared with 0.00% for ARKG.

BIB is categorized as Leveraged Equities, while ARKG is Health & Biotech Equities. They also come from different issuers: ProShares and ARK. Their fees differ too: 0.95% for BIB and 0.75% for ARKG.

BIB currently has the higher Sharpe Ratio (2.51 vs 1.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BIB and ARKG

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer